Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 25

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 15
Chunk 25
---
(10)
     
    Form of Class F Common Stock Warrant dated December 3, 2024

    4.15(10)
     
    Form of Class G Common Stock Warrant dated December 3, 2024

    4.16*
     
    Description of Securities

    10.1†(11)
     
    Revelation Biosciences, Inc. 2021 Equity Incentive Plan, as amended

    10.2†(1)
     
    Executive Employment Agreement between Revelation Biosciences, Inc. and James Rolke, effective July 27, 2021

    10.3†(1)
     
    Executive Employment Agreement between Revelation Biosciences, Inc. and Chester S. Zygmont, III, effective July 27, 2021

    10.4(1)
     
    Revelation Common Stock Warrant Issued to National Securities Corporation

    10.5(5)
     
    Securities Purchase Agreement dated January 23, 2022 by and between the Company and Armistice Capital Master Fund Ltd.

    10.6(7)
     
    Form of Securities Purchase Agreement dated February 9, 2023

    10.7(7)
     
    Form of Placement Agency Agreement Dated February 9, 2023

    10.8(8)
     
    Form of Securities Purchase Agreement dated February 1, 2024

    10.9(8)
     
    Form of Placement Agency Agreement dated February 1, 2024

    14.1(12)
     
    Code of Ethics

    14.2*
     
    Insider Trader Policy

    21.1(13)
     
    List of Subsidiaries.

    23.1*
     
    Consent of Baker Tilly US, LLP, independent registered public accounting firm of Revelation Biosciences, Inc.

    31.1*
     
    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    31.2*
     
    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section